Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stoke Therapeutics, Inc.

8.60
+0.49006.04%
Post-market: 8.600.00000.00%18:17 EDT
Volume:876.96K
Turnover:7.50M
Market Cap:455.52M
PE:-4.16
High:8.72
Open:8.18
Low:8.18
Close:8.11
Loading ...

Top Premarket Decliners

MT Newswires Live
·
11 Mar

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Business Wire
·
27 Feb

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Simply Wall St.
·
26 Feb

Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)

TIPRANKS
·
23 Feb

Chardan Capital Sticks to Their Buy Rating for Stoke Therapeutics (STOK)

TIPRANKS
·
19 Feb

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Benzinga
·
19 Feb

Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham

Dow Jones
·
19 Feb

HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating

MT Newswires Live
·
18 Feb

BRIEF-Biogen And Stoke Therapeutics Enter Into Collaboration

Reuters
·
18 Feb

Stoke Therapeutics Shares up 3.5% After Co Enters Partnership With Biogen to Develop, Sell Epilepsy Drug

THOMSON REUTERS
·
18 Feb

Biogen Shares up About 1%

THOMSON REUTERS
·
18 Feb

Stoke Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $47 From $35

THOMSON REUTERS
·
18 Feb

Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration

Dow Jones
·
18 Feb

Stoke Therapeutics and Biogen in pact for treatment for severe form of epilepsy

Dow Jones
·
18 Feb

Stoke Therapeutics And Biogen In Pact For Treatment For Severe Form Of Epilepsy -- MarketWatch

Dow Jones
·
18 Feb

Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement

TIPRANKS
·
18 Feb